12 Stocks that Will Bounce Back According to Wall Street Analysts

3. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

6-Month Performance: -34.51%

Average Price Target Upside Potential According to Analysts: 179.28%

Number of Hedge Fund Holders: 28

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) ranks among the stocks that will bounce back according to Wall Street analysts. On January 2, Roth MKM reiterated its Buy rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) with a price target of $30 on the stock.

In other news, on December 29, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) reported that China’s National Medical Products Administration (NMPA) has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions, anaphylaxis. The approval covers adults and children who weigh at least 30 kilograms.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has an exclusive licensing agreement with Pediatrix Therapeutics, giving Pediatrix the exclusive rights to commercialize neffy in China for severe allergic reactions and certain other conditions like chronic spontaneous urticaria. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will receive a final regulatory milestone payment of $4 million and expects to receive up to $80 million in additional sales-based milestone payments. The company is also entitled to receive tiered royalties in the low double-digit range based on annual net sales.

According to the report, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will manufacture and supply neffy to Pediatrix in China at the cost of goods. The company expects neffy to become available in China in the spring of 2026. Additionally, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) and Pediatrix plan to also file for approval of neffy 1 mg dose for children weighing more than 15 kilograms and less than 30 kilograms in the coming months.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a biopharmaceutical company focused on developing treatments for allergies that could lead to anaphylaxis.